Aquestive Therapeutics, Inc (AQST)

Etorro trading 970x250

About Aquestive Therapeutics, Inc

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company’s proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Address: 30 Technology Drive, Warren, NJ, United States, 07059

Aquestive Therapeutics, Inc News and around…

Latest news about Aquestive Therapeutics, Inc (AQST) common stock and company :

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
17 Nov, 2021 Yahoo! Finance

WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd. The Aquestive team is scheduled to a hold a fireside chat that is available on demand starti

Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript
04 Nov, 2021 FinancialContent

AQST earnings call for the period ending September 30, 2021.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance
02 Nov, 2021 Yahoo! Finance

Libervant™ (diazepam) Buccal Film continues to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021AQST-109 top line Phase 1 trial demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of allergic reactions, including anaphylaxisImproves full year revenue and earnings guidanceHosts conference call at 8:00 a.m. ET on November 3, 2021 WARREN, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aquestive Therape

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Is Expected To Breakeven In The Near Future
02 Nov, 2021 Yahoo! Finance

We feel now is a pretty good time to analyse Aquestive Therapeutics, Inc.'s ( NASDAQ:AQST ) business as it appears the...

Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
26 Oct, 2021 Yahoo! Finance

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions
25 Oct, 2021 Yahoo! Finance

First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of allergic reactionsMedian time to peak concentration (Tmax) of 15 minutes or less achieved across multiple formulations of AQST-109 at 12 mg dose, comparable to autoinjectorsTmax range for all formulations was narrower than published data for autoinjectorsMean peak concentration levels (Cmax) meet or exceed th

2 “Strong Buy” Penny Stocks That Could Spike Over 200%
20 Oct, 2021 Yahoo! Finance

Wall Street has mixed feelings about penny stocks. These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running for the hills, but why? When we say high return potential, we aren’t exaggerating. The bargain price points allow investors to snap up more shares than possible when investing in other more well-known names. What’s more, even what feels like trivial share price appreciation can translate to massive percentage gai

Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
14 Oct, 2021 Yahoo! Finance

WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for third quarter ended September 30, 2021 and provide an update on recent developments in its business after market close on Tuesday, November 2, 2021. Management will host a conference call for investors

Implied VTI Analyst Target Price: $255
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $255.38 per unit.

Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement
06 Oct, 2021 Yahoo! Finance

WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders providing for a bridge waiver of the first principal payment due under its 12.5% Senior Secured Notes (the “Notes”) in order to provide sufficient time for the parties to execute a de

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.
29 Sep, 2021 FinancialContent
Aquestive Therapeutics to Participate in Three Investor Conferences in September
07 Sep, 2021 FinancialContent
What Kind Of Shareholders Hold The Majority In Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares?
03 Sep, 2021 Yahoo! Finance

Every investor in Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) should be aware of the most powerful shareholder groups...

12 Health Care Stocks Moving In Monday's Intraday Session
30 Aug, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's ...

Looking into Aquestive Therapeutics's Return on Capital Employed
20 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $15.35 ...

How The Parts Add Up: ITOT Targets $112
19 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement
09 Aug, 2021 FinancialContent
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
06 Aug, 2021 FinancialContent
88 Biggest Movers From Yesterday
05 Aug, 2021 FinancialContent

Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
04 Aug, 2021 FinancialContent

Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The ...

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
03 Aug, 2021 Yahoo! Finance

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance
03 Aug, 2021 FinancialContent
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline
27 Jul, 2021 Yahoo! Finance

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8:00 a.m. ET
21 Jul, 2021 FinancialContent
4 Stocks to Watch During a Market Crash
19 Jul, 2021 FinancialContent
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film
19 Jul, 2021 FinancialContent
How The Parts Add Up: IWC Headed For $201
06 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $200.72 per unit.

Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
24 Jun, 2021 FinancialContent

Aquestive Therapeutics, Inc (AQST) is a NASDAQ Common Stock listed in , ,

970x250